Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1990-6-29
|
pubmed:abstractText |
We have investigated the effects of interleukin 1 (IL-1) administration on the ability of neutropenic mice to resist Pseudomonas aeruginosa challenge in vivo. Cyclophosphamide-treated mice received human rIL-1 beta at 7.0, 0.7, or 00.7 micrograms/kg, according to different regimens, to be challenged with a lethal ip inoculum of pseudomonas cells 5 days after myelosuppression. The repeated exposure of the neutropenic mice to an overall cytokine dosage of 7.0 or 0.7 micrograms/kg during the 4 days after myelosuppression was found to optimally restore the animals' antibacterial resistance. However, when administered as a single injection 24 hr before challenge, the same dosages of IL-1 had lower or no effect in enhancing survival, primarily leading only to a reduction in the amount of antipseudomonal chemotherapy required for cure. The regimen of IL-1 administration conferring optimal protection also resulted in a decrease in the number of pseudomonas cells recovered from the peritoneal cavity of infected mice. This regimen accelerated hematopoietic recovery in cyclophosphamide-treated mice. Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1. These results suggest that regulation of hematopoiesis may have an important role in the induction of antibacterial resistance in myelosuppressed hosts repeatedly treated with low dosages of IL-1.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-8749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
128
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
250-60
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2111738-Animals,
pubmed-meshheading:2111738-Blood Bactericidal Activity,
pubmed-meshheading:2111738-Colony-Forming Units Assay,
pubmed-meshheading:2111738-Cyclophosphamide,
pubmed-meshheading:2111738-Dose-Response Relationship, Drug,
pubmed-meshheading:2111738-Female,
pubmed-meshheading:2111738-Gentamicins,
pubmed-meshheading:2111738-Hematopoiesis,
pubmed-meshheading:2111738-Immunotherapy,
pubmed-meshheading:2111738-Interleukin-1,
pubmed-meshheading:2111738-Leukocyte Count,
pubmed-meshheading:2111738-Mice,
pubmed-meshheading:2111738-Mice, Inbred BALB C,
pubmed-meshheading:2111738-Neutrophils,
pubmed-meshheading:2111738-Pseudomonas Infections,
pubmed-meshheading:2111738-Pseudomonas aeruginosa,
pubmed-meshheading:2111738-Recombinant Proteins,
pubmed-meshheading:2111738-Time Factors
|
pubmed:year |
1990
|
pubmed:articleTitle |
Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream.
|
pubmed:affiliation |
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
|
pubmed:publicationType |
Journal Article
|